Filing Overview
Deep Medicine Acquisition Corp. (DMAQ) filed this Form 8-K on December 7, 2023 regarding amendments to its proposed business combination with TruGolf, Inc. The filing is not a periodic financial report and does not provide a reporting-period income statement, balance sheet, or cash flow update.
Material Agreements and Financing
- Merger agreement amendment: TruGolf Class B common stock and corresponding post-closing Class B common stock will carry 25 votes per share, increased from 10 votes per share.
- Board composition: The post-closing company’s board will be reduced from seven members to five. DMAQ’s designated seats will decline from three to one.
- Additional PIPE financing: DMAQ entered into loan agreements with Li Holding, L&H, and JAK Opportunities for up to $5.0 million of convertible notes and warrants to purchase 454,545 Class A shares after the business combination closes.
- Finuvia amendment: The maximum Finuvia convertible-note principal was reduced from $2.5 million to $0.5 million, and related warrants were reduced from 227,273 to 45,455 shares.
- Total PIPE commitment: Including the November 2, 2023 investments, the aggregate financing is up to $11.0 million of convertible-note principal and warrants to purchase 1,000,000 Class A shares.
- The securities to be issued to PIPE investors are described as unregistered and intended to rely on the Section 4(a)(2) exemption.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, margins, operating cash flow, cash balances, debt balances before these transactions, or other periodic financial metrics. The disclosed financing would create up to $11.0 million of convertible-note obligations and potential dilution from warrants for 1,000,000 Class A shares, subject to the agreements and closing of the business combination.
Outlook, Risks, and Contingencies
- Completion of the business combination remains subject to customary conditions, including DMAQ stockholder approval, and may not occur or may be delayed.
- The merger agreement may be terminated under specified circumstances, and legal proceedings could affect the transaction.
- The filing highlights uncertainty regarding TruGolf’s future revenue, capital expenditures, financial condition, liquidity, operating results, products, market opportunities, and the potential level of public-stockholder redemptions.
- The proposed financing, conversion features, and warrants could increase leverage and dilute existing shareholders.
- The registration statement and proxy statement/prospectus contain or are expected to contain additional transaction terms and risk factors; investors are directed to those SEC filings.
Investor Verification Priorities
- Verify whether the business combination closes and confirm the final ownership, capitalization, and board structure.
- Review the definitive proxy statement/prospectus for TruGolf’s historical and projected financial information, valuation, and redemption assumptions.
- Review the loan agreements for interest, maturity, conversion mechanics, security, default provisions, and warrant exercise terms.
- Confirm the final amount of PIPE financing funded and the resulting share dilution.
- Assess the effect of the increased Class B voting rights on control of the combined company.